Has Olga Petryna, MD received payments from drug or device companies?

Yes. Drug and device makers reported $508,867 in general payments to Olga Petryna, MD across 545 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Olga Petryna, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Olga Petryna, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Olga Petryna, MD

Rheumatology · New York, NYNPI 1386878577

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $410,884 of the $508,867 with a category attached, or 80.7%. 24 manufacturers reported payments, led by Johnson & Johnson at 24.1% of the total. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$508,867in general payments, 2019–2025

Across 545 payments — averaging $933.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$123K
Mallinckrodt Hospital Products Inc.$82K
Novartis$76K
Amgen$69K
Lilly USA, LLC$59K
AstraZeneca$39K
plus $62K from 18 others

What the payments were for

Consulting fees$51,82110%
Speaking & faculty fees$410,88481%
Travel & lodging$27,7995%
Food & beverage$17,9944%
Education$3700%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	86	$122,557
Mallinckrodt Hospital Products Inc.	60	$82,164
Novartis	99	$76,246
Amgen(2 entities)	87	$68,538
Lilly USA, LLC	56	$58,897
AstraZeneca	36	$38,629
Mallinckrodt Enterprises LLC	14	$19,799
Pfizer	25	$15,066
Bristol Myers Squibb	14	$11,620
Ultragenyx Pharmaceutical Inc.	2	$5,400
UCB, Inc.	3	$4,726
Sanofi	25	$2,444
Aurinia Pharma U.S., Inc.	11	$956
AbbVie	4	$468
Pacira Therapeutics, Inc.	2	$306
Janssen Scientific Affairs, LLC	3	$240
Medexus Pharma, Inc.	9	$224
ANI Pharmaceuticals, Inc.	2	$188
Regeneron	1	$119
Sanofi-aventis U.S. LLC	2	$112
Regeneron Healthcare Solutions, Inc.	1	$71
Biohaven Pharmaceuticals, Inc.	1	$55
Octapharma USA, Inc.	1	$30
GSK	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$121,890
SIMPONI ARIA$121,765
ACTHAR$101,497
KRYSTEXXA$61,379
COSENTYX$60,881
TALTZ$54,455
SAPHNELO$38,253
Otezla$17,396
XELJANZ$15,000
ILARIS$8,056
Bimzelx$3,420
KEVZARA$1,497
RAYOS$1,047
Tavneos$772
LUPKYNIS$659
Zilretta$306
Humira$222
Rinvoq$148
PURIFIED CORTROPHIN GEL$116
Rasuvo$101

How this compares

$508,867 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York →

Medicare billing

Part B allowed, 2024

$52,782

Medicare patients

158

Services billed

903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Taltz AutoinjectorIxekizumab	18	$198,449
Cosentyx Sensoready (2 Pens)Secukinumab	27	$196,108
Humira(Cf) PenAdalimumab	17	$138,228
Cosentyx Sensoready PenSecukinumab	12	$107,334
Hydroxychloroquine Sulfate	96	$3,554
MethotrexateMethotrexate Sodium	70	$2,779
Prednisone	106	$802
Colchicine	22	$789
Sulfasalazine DrSulfasalazine	18	$598
Alendronate Sodium	61	$423
Allopurinol	52	$357
Folic Acid	25	$261
Ibandronate Sodium	11	$104

Paid to pharmacies, not to this prescriber.

Other rheumatology in New York

Laurie GlimcherNew York$3.9M
Grace WrightNew York$3M
Sergio SchwartzmanNew York$2.5M
Allan GibofskyNew York$1.9M
Petros EfthimiouNew York$791K
Danielle PeterselNew York$461K
Jose ScherNew York$446K
Jason FallerNew York$357K
Lindsay LallyNew York$340K
Laura Geraldino PardillaNew York$224K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →